HPB and Transplant Unit, St. James's University Hospital, Leeds, UK.
HPB (Oxford). 2014 Mar;16(3):220-8. doi: 10.1111/hpb.12124. Epub 2013 Jul 22.
An acetominophen overdose (AOD) is the leading cause of acute liver failure (ALF) in the UK and USA. For patients who meet the King's College Hospital criteria, (mortality risk > 85%), an emergency orthotopic liver transplantation (OLT) is conventionally performed with subsequent life-long immunosuppression. A new technique was developed in 1998 for AOD-induced ALF where a subtotal hepatectomy (right hepatic trisectionectomy) and whole graft auxiliary liver transplant (WGALT) was performed with complete withdrawal of immunosupression during the first year post-operatively.
During 1998-2010, 68 patients were listed for an emergency transplantation for AOD ALF at our institution: 28 died waiting, 16 underwent OLT and 24 a subtotal hepatectomy with WGALT. Eight OLT (50%) and 16 WGALT remain alive (67%); actuarial survival at 5 years OLT 50%, WGALT 63%, P = 0.37. All patients who had successful WGALT are off immunosuppression. Poor prognostic factors in the WGALT group included higher donor age (40.4 versus 53.9, P = 0.043), requirements for a blood transfusion (4.3 versus 7.6, P = 0.0043) and recipient weight (63.1 versus 54 kg, P = 0.036).
Although OLT remains standard practice for AOD-induced ALF, life-long immunosuppression is required. A favourable survival rate using a subtotal hepatectomy and WGALT has been demonstrated, and importantly, all successful patients have undergone complete immunosuppression withdrawal. This technique is advocated for patients who have acetominophen hepatotoxicity requiring liver transplantation.
对乙酰氨基酚过量(AOD)是英国和美国急性肝衰竭(ALF)的主要原因。对于符合国王学院医院标准的患者(死亡率>85%),传统上会进行紧急原位肝移植(OLT),随后进行终身免疫抑制。1998 年,一种新的技术被开发用于 AOD 诱导的 ALF,即进行部分肝切除术(右三叶切除术)和全移植物辅助肝移植(WGALT),术后第一年完全停止免疫抑制。
在 1998 年至 2010 年期间,我院有 68 名患者因 AOD-ALF 接受紧急移植:28 名等待死亡,16 名接受 OLT,24 名接受部分肝切除术和 WGALT。8 例 OLT(50%)和 16 例 WGALT 仍存活(67%);OLT 5 年生存率为 50%,WGALT 为 63%,P=0.37。所有成功进行 WGALT 的患者均已停止免疫抑制。WGALT 组的不良预后因素包括供体年龄较高(40.4 岁比 53.9 岁,P=0.043)、需要输血(4.3 比 7.6,P=0.0043)和受体体重(63.1 比 54kg,P=0.036)。
尽管 OLT 仍然是 AOD 诱导的 ALF 的标准治疗方法,但需要终身免疫抑制。部分肝切除术和 WGALT 已显示出良好的生存率,重要的是,所有成功的患者均已完全停止免疫抑制。对于需要肝移植的对乙酰氨基酚肝毒性患者,建议采用该技术。